|
Apr 18
|
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
|
|
Feb 21
|
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a "Pipeline in a Product"
|
|
Jan 16
|
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
|
|
Jan 16
|
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
|
|
Jan 5
|
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
|
|
Dec 20
|
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
|
|
Dec 7
|
Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS
|
|
Dec 6
|
Coya Therapeutics Announces $26.5 Million Private Placement
|
|
Dec 6
|
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
|
|
Nov 8
|
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
|
|
Oct 19
|
Is Coya Therapeutics (NASDAQ:COYA) In A Good Position To Invest In Growth?
|
|
Aug 8
|
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
|
|
May 22
|
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023
|
|
May 16
|
Why Coya Therapeutics Shares Are Shooting Higher Today
|
|
May 16
|
Here's Why Momentum in Coya Therapeutics, Inc. (COYA) Should Keep going
|
|
May 16
|
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
|